Saturday, March 03, 2007

Gene profiling predicts resistance to breast cancer drug Herceptin

Using gene chips to profile tumors before treatment, researchers at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary treatment for HER2-positive breast cancer. They say this advance could help further refine therapy for the 25 to 30 percent of breast cancer patients with this class of tumor. --Click the title of this post to read the full article from its source--

Labels: , , , ,

Wednesday, December 13, 2006

U.S. breast-cancer guidelines updated

The U.S. national guidelines for treating breast cancer have been updated to reflect new technology, a cancer group said Wednesday. One change is that Eli Lilly's Evista (raloxifene) is now recommended for use in reducing the risk of invasive breast cancer in postmenopausal women with lobular carcinoma in situ, the National Comprehensive Cancer Network said in a statement Wednesday. The update is based on positive results from the NSABP Study of Tamoxifen and Raloxifene (STAR) trial, the group said. The NCCN further advised that, when a breast MRI is indicated, the test should be performed and interpreted by an expert breast-imaging team working in concert with the multidisciplinary treatment team. The revised guidelines also contain advice on incorporating Genentech's Herceptin (trastuzumab) as an adjuvant treatment for HER2-positive breast cancer and recommend that current treatments now used in the adjuvant setting also be considered for the neoadjuvant setting. The NCCN is a non-profit alliance comprised of 20 of the world's leading cancer centers. --Click the title of this post to read the full article from its source--

Labels: , , , , , ,

/* WebRing Code */